✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #20
Engineering CAR T Cells Inside Solid Tumors
CAR T-cell therapy, already approved for blood cancers, faces major hurdles in solid tumors, where hostile microenvironments suppress engineered immune cells. A new approach reported in pharmaceutical manufacturing coverage aims to build or arm CAR T cells directly inside tumor tissue, potentially improving persistence and reducing off-target effects. Researchers see in-situ engineering as a promising route to finally extend cell therapy beyond blood cancers, though clinical proof remains limited.
Why now: Growing interest in making CAR T-cell therapy work against solid tumors, where current approaches have largely failed.
CAR T-cell therapyThe Medicine Makersolid tumorscancer immunotherapy
Rank over time, top of the chart is #1. 2 snapshots from 1 d ago to 1 d ago.
Evidence
- Engineering CAR T Cells Inside Solid Tumors · The Medicine Maker
API: https://socialmediatrends-api.osmike.com/v1/trends/3736298